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Abstract
Background: Mammaglobin (MAM) has been used as a specific molecular marker for breast
cancer diagnosis. Recently, several groups of researchers proposed a number of therapeutic
strategies targeting this molecule. Some of the strategies are based upon an essential but not
demonstrated hypothesis – mammaglobin is associated with the surface of breast cancer cells,
which strongly disputes the therapeutic strategies.
Results: We conducted a computer-based predictive analysis and identified a small fragment at the
N-end of MAM as a potential transmembrane domain. We provided several evidences to
demonstrate the presence of the membrane-associated MAM. We isolated the membrane protein
components from known MAM positive breast cancer cells (MDA-MB361 and MDA-MB415). We
showed that about 22–64% of MAM proteins, depending upon the types of the cancer cells, directly
attached on the membrane of breast cancer cells, by Western blotting assays. To directly visualize
the presence of the membrane-bound MAM protein, we incubated the MAM positive cancer cells
with FITC labeled anti-MAM antibody, and observed clear fluorescent signals on the surface of the
cells. In studying the MAM protein distribution in human breast cancer tissues, we first identified
two immunostain patterns that are associated with the membrane-bound MAM: the membrane
stain pattern and luminary surface stain pattern. To test whether the membrane-associated MAM
can serve as a molecular target for drug delivery, we conjugated anti-MAM antibody to human low-
density lipoprotein (LDL) and loaded doxorubicin (Dox) in the core of LDL. Specific binding and
cytotoxicity of the MAM targeted and Dox loaded LDL was tested in the MAM positive breast
cancer cells in vitro.
Conclusion: We first showed that some of MAM protein directly associated with the surface of
breast cancer cells. The membrane-associated MAM protein may be utilized as a useful molecular
marker for breast cancer targeted drug delivery.
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Background
Watson and Fleming first named the protein encoded by
a novel cDNA isolated from a primary human breast can-
cer as mammaglobin (MAM) [1]. Since MAM protein is
homologous to a family of secreted proteins, it is classi-
fied as a member of the secretoglobin family. So far, the
function of MAM has not been well known. It is assumed
that MAM is involved in regulating the host steroid
metabolisms and immune functions [2]. Colpitts et al
reported that MAM binds to a lipophilin B or BU101 pro-
tein in a head to tail format and forms a complex [3,4].
Analyses of the purified complex indicated that the assem-
bly was proceeded with cleavage of the signal peptides
from both MAM and lipophilin B proteins. The assembled
protein complex formed a small helical globule and create
a hydrophobic pocket capable of binding steroid-like
molecules and biphenyls [4]. Several years later, Berker et
al identified another human uteroglobin-like gene and
named it as mammaglobin B (Mam-B), which is highly
homologous to the Mam gene or Mam-A characterized by
Watson and Fleming [5]. It has been reported that the
expression of the Mam-A gene is highly restricted to the
adult mammary gland [6], whiles the expression of the
Mam-B  gene is found in many organs, such as breast,
uterus, salivary gland, lacrimal gland, testis, ovary, and
thyroid [5]. More attention, therefore, has been focused
on the Mam or Mam-A as a diagnostic marker of breast
cancer. In a RT-PCR based analysis on the axillary lymph
nodes from twenty breast cancer patients, thirteen known
metastatic lymph nodes showed Mam  mRNA positive
while all of the remaining pathologic negative nodes were
negative for Mam  [7]. The RT-PCR-based Mam  mRNA
assay was also used for detection of circulating breast can-
cer cells in the peripheral blood of patients [8].
Recently, MAM has also been investigated as a molecular
marker for developing breast cancer targeted therapeutic
tools. However, lack of evidence that MAM protein exists
on the surface of breast cancer cells strongly disputes on
these therapeutic strategies, especially when anti-MAM
antibody is used as a targeting ligand for drug delivery. In
this study, we demonstrated the presence of the mem-
brane-associated MAM and proved that the membrane-
associated MAM can serve as a molecular target for breast
cancer targeted drug delivery.
Methods
Computer-Based Analysis on Mammaglobin Protein
The protein sequence of mammaglobin was downloaded
and reformatted in Fasta sequence and up-loaded to the
"HMM-based Protein Structure Prediction" webpage for a
SAM-T02 analysis http://compbio.soe.ucsc.edu/HMM-
apps/T02-query.html. The secondary structures of MAM
protein were predicted and analyzed.
Cell Culture
Cancer and non-cancerous cell lines were grown at 37°C
with or without 5% CO2. MDA-MB-361 (MB361), MDA-
MB-415 (MB415), T47D, and MDA-MB-231 (MB231)
(human breast cancer cell lines, ATCC) were maintained
in DMEM:Ham's F-12 medium (50:50; Mediatech) with
10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml
penicillin, and 100 μg/ml streptomycin (GIBCO, Life
Technologies Inc., Carlsbad, CA). HAEC (human aortic
endothelial cell line, Clonetics) and cell culture medium
(EGM-2 Bulletkit) were purchased from Cambrex (East
Rutherford, NJ). All cell lines were used at early passages
(5–10).
Isolation of the Membrane and Cytosolic Protein Fractions 
from Cultured Cells
Cells were treated with ice-cold hypotonic lysis buffer (10
mM Tris pH 7.4, 1.5 mM MgCl2, 5 mM KCl, 1 mM DTT,
0.2 mM sodium vanadate, 1 mM PMSF, 1 ug/ml apro-
tinin, 1 ug/ml leupeptin) for 5 minutes. After drawing the
lysate through a 1-mL syring with several rapid strokes,
the samples were centrifuged at 2000 g at 4°C for 5 min-
utes. The supernatant was centrifuged at 100,000 g at 4°C
for 90 minutes, and the supernatant was saved as
"cytosolic" fraction. The pellets were saved as "mem-
brane" fraction.
Western Blot Assays
Growth-arrested cells were lysed with 500 μl of ice-cold
lysis buffer, pH 7.4 ((in mM) 50 HEPES, 5 EDTA, 50
NaCl), 1% Triton X-100, protease inhibitors (10 μg/ml
aprotinin, 1 mM phenylmethylsulfonyl fluoride, 10 μg/
ml leupeptin) and phosphatase inhibitors ((in mM) 50
sodium fluoride, 1 sodium orthovanadate, 10 sodium
pyrophosphate). Cell lysates (25 μg) were separated using
SDS-polyacrylamide gel electrophoresis and transferred to
nitrocellulose membranes, blocked overnight in PBS con-
taining 6% nonfat dry milk and 0.1% Tween 20, and incu-
bated for 1 h with primary antibodies. After incubation
with secondary antibodies, proteins were detected by ECL
chemiluminescence.
Immunohistochemistry
Immunohistochemical staining for MAM protein was per-
formed as described previously [9,10]. In brief, tissue
array sections consisting of 36 human breast cancer and
36 adjacent breast benign tissue cores (Ray Biotech, GA)
were deparaffinized and rehydrated. After antigen
retrieval and endogenous peroxidase blocking, the sec-
tions were blocked with 5% normal horse serum. The
slides were incubated with anti-MAM antibody (diluted at
1:500 dilution) at 4°C overnight, then incubated with
secondary antibody (ImmPRESS REAGENT kit, VECTOR
Lab, CA) and the ImmPACT DAB kit (VECTOR Lab, CA).Cancer Cell International 2009, 9:8 http://www.cancerci.com/content/9/1/8
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The immunostained slides were counterstained with
hematoxylin and evaluated using a Nikon microscope
with an Olympus digital camera.
Anti-MAM Antibody Incubation and Cell Viability Assay
The cells were cultured in chambered slides and incubated
with anti-MAM antibody (Zeta corp. CA, clone 304-1A5)
at a concentration of 150 ng/ml for 24 hours at 37°C. The
cells were then washed three times with 1× PBS buffer and
stained with the Live/Dead Cell Viability/Cytotoxicity Kit
according to the instructions from the manufacturer
(Molecular Probes Carlsbad, CA). The live cells were
shown in green and dead cells were shown in red under
fluorescent microscopy. The percentage of dead cells was
estimated as follow: Cell viability (%) = (dead cell count/
total cell count) × 100.
Anti-MAM Conjugation to ApoB-100 Protein on the 
Surface of LDL Particles
In order to conjugate anti-MAM antibody to the apoB-100
protein on LDL particles, a water-soluble carbodiimide
was used to activate the carboxyl groups on the surface of
apoB-100 protein [11,12]. In brief, 1 mg LDL (Sigma-
Alorich, St. Louis, MO) was added to 1 ml of 0.3 M
sodium acetate with continuous stirring in an ice-water
bath. The acetic anhydride was added in multiple small
aliquots (2 μL) over a period of 1 hr with continuous stir-
ring. The reaction mixture was then dialyzed for 24 hr at
4°C against dialyzing buffer. The activated LDL particles
were added to 0.4 mg 1-ethyl-3(3-dimethylaminopropyl)
carbodiimide (EDC) and 1.1 mg of sulfo-NHS in 1 ml of
0.15 M NaCl. After 60 minute incubation at room temper-
ature, 1.4 μl of 2-mercaptoethanol was added to quench
the EDC. Equal mole of anti-MAM was added to the LDL
reaction mixture and incubated for 2 hours at room tem-
perature. The reaction was stopped by adding hydroxy-
lamine, excess quenching reagent was removed by
dialysis, and the synthesized LDL particles (anti-MAM-
LDL) were collected.
Loading Doxorubincin (Dox) into the Synthetic LDL 
Particles
Dox was added to 1 ml synthesized LDL particles from a
stock solution (0.1 ml, 10 mg/ml) and mixed and incu-
bated in a shaker at 37°C for 4–6 hrs in dark. The mixture
was then loaded onto a gel filtration column with G25
Sephadex to separate the unloaded Dox from the Dox
loaded synthetic LDL. Fractions of 0.5 ml were collected.
The Dox loaded LDL particles (anti-MAM-LDL-Dox) were
sterilized by passing through a 0.45 μm acetate millipore
filter. The concentration of Dox in the synthetic LDL was
then measured as follow: twenty micro liters of the anti-
MAM-LDL-Dox particles were added to 780 μl of acidified
isopropanol. A standard curve of the Dox concentration in
acidified isopropanol versus the absorbance (O.D.) at
wavelength 480 nm was obtained. This curve was used to
determine the concentration of the synthetic LDL [13].
The morphology and particle size of the synthetic LDL
particles were analyzed by electron microscopy using a
Philips EM 300 and photographed at 75,000× magnifica-
tion [14].
In Vitro Testing the MAM Targeted Therapeutic LDL 
Nanoparticles
The human breast cancer MB415 cells and human aortic
endothelial cells HAEC were grown in the 4-well cham-
bered slides and incubated with the MAM targeted thera-
peutic LDL at concentration 0.3 mg/ml of Dox for 24
hours. The cultured cells were then harvested for cell via-
bility assays. As controls, both cells were also incubated
with free Dox at 1 mg/ml, native LDL-DiI at 250 ng/ml,
and LDL-Dox at 1 mg/ml.
Results
MAM is predicted as a transmembrane protein
Proteins are usually composed of one or more functional
regions, or domains. The identification of domains that
occur within proteins can provide insights into their func-
tions. The meta-server technique represents one of the
major progresses in the field of protein tertiary structure
prediction. To predict the secondary structure of the pro-
tein, we conducted a predictive analysis on the MAM pro-
tein sequence with the SAM-T02 [15]. Based on the
predictive analysis, we identified five helixes or domains
on the protein (Figure 1). Among these domains, the frag-
Computer-assisted structural analysis of MAM protein Figure 1
Computer-assisted structural analysis of MAM pro-
tein. The predicted secondary structure of MAM/lipophilin B 
dimmer (upper left) and MAM alone (upper right) created by 
the HMM-based protein structure prediction program, SAM-
T02. A helix fragment at the N-end of MAM protein is pre-
dicted as a transmembrane domain (the dark blue helix). The 
protein sequence shown is the N-terminal end of MAM. "+" 
Inside loop; "-" Outside loop; "O" Outside helix cap; "X" 
Central transmembrane helix segment; "I" Inside helix cap.Cancer Cell International 2009, 9:8 http://www.cancerci.com/content/9/1/8
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ment at the N-end of MAM protein (the 9–18th amino acid
residues) is different from those of the lipophilin and
other uteroglobin family proteins (such as pheromaxein C
subunit, prostatein C3 subunit, uteroglobin). This frag-
ment mostly consists of the hydrophobic amino acids and
is predicted as the trans-membrane helix. So we proposed
that MAM proteins are, at least some if not all, associated
with cell membrane.
MAM is associated with membrane in human breast 
cancer cells
To examine whether MAM is a membrane-associated pro-
tein in breast cancer cells, we isolated the membrane and
cytosol proteins from the cultured MDA-MB415
(MB415), MDA-MB361 (MB361), and MDA-MB231
(MB231) breast cancer cells respectively. We used Na+-K+-
ATPase as the membrane marker and α-tubulin as the
cytosol marker. By performing Western blot assays, we
detected MAM protein existing at both membrane and
cytosol fractions in MB361 and MB415 cancer cells, but
not in the MB231 cells (Figure 2). The membrane and
cytosol associated MAM proteins were quantitatively eval-
uated based on the scanned intensities of the specific
bands for MAM by normalization of GADPH bands. The
membrane-associated MAM protein of MB415 cells was
estimated 49.4% more than that of the MB316 cells. The
ratios of the membrane-associated MAM protein vs.
cytosolic MAM were about 22.2% and 64.1% in the
MB361 and MB415 cells respectively.
To test whether MAM proteins are detectable on living
breast cancer cells in vitro, we incubated the known MAM
positive human breast cancer cells MDA-MB361 (MB361)
with the FITC labeled anti-MAM monoclonal antibody,
and then monitored the cell fluorescent signals at 1, 4,
and 24 hours after the incubation. Obvious fluorescent
signals were observed on the MB361 cells as early as 1
hour after the incubation, but the strongest signals were
seen after the 24 hours incubation (see Additional file 1).
To confirm MAM protein is associated with the mem-
brane in vivo, we studied the tissue microarray sections of
human breast cancers with anti-MAM antibody by immu-
nohistochemistry. Ten of 36 breast cancer tissue cores
were stained positive for anti-MAM antibody while five of
36 breast benign tissue cores were weakly positive. The
intensities of the MAM immuno-staining were quite het-
erogeneous among the breast cancer cores from marginal
to abundant positive with overall stronger stain in the
breast cancers, as compared with that of the breast benign
tissues. There are three types of anti-MAM immuno-stain-
ing patterns observed: (1) cytoplasmic stain pattern (Fig-
ure 3A and 3C); (2) membrane stain pattern showed at
the surface of some breast cancer cells (Figure 3B); and (3)
luminary stain pattern showed at the luminary surface of
some benign mammary glands (Figure 3D). These data
strongly suggest that some of MAM proteins are associated
with the cell membrane in both benign and malignant
breasts.
Anti-MAM induced a weak cell apoptotic response in 
human breast cancer cells
After the incubation with 150 ng/ml of anti-MAM anti-
body, about 30–40% of MB361 cancer cells were
detached from the cell culture slides. We assumed the cell
apoptosis is induced. To test this assumption, we incu-
bated MB361 cells with anti-MAM antibody. After 24
hour incubation, we conducted cell viability assays and
found only about 10% of the attached cells dead (Figure
4 Panel One). In addition, we performed western blot
assays to examine the expression of cell apoptosis relevant
proteins under this condition from the cultured MB361,
T47D, and HAEC cells. PARP-1 is a marker protein for cell
apoptosis. The pro-PARP-1 protein is about 100 kDa and
the activated form is 89 kDa. The activated PARP-1 was
detected only in the MB361 cells incubated with anti-
MAM antibody (Figure 4 Panel Two). However, there were
no changes in the expression of other apoptosis relevant
proteins such as caspase 3 and Bax-1 (data not shown) in
the MB361 cells. These data indicated that only limited
cell apoptosis was induced with the antibody incubation.
Detection of membrane associated MAM protein on breast  cancer cells Figure 2
Detection of membrane associated MAM protein on 
breast cancer cells. The Western blot assay shows the 
specific MAM protein bands (10.5 kDa) in both membranous 
and cytoplasmic proteins of MDA-MB361 (361) and MDA-
MB415 (415) cells; while no specific bands in the membra-
nous and cytoplasmic proteins of MB231 cells. The bar graph 
represents the quantitative measurements of Western blot 
assays from four separated experiments (mean ± SE).Cancer Cell International 2009, 9:8 http://www.cancerci.com/content/9/1/8
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The mechanisms that are involved in the cell detachment
remain unclear.
Membrane-associated MAM protein can be targeted for 
therapeutics in human breast cancer cells
Our primary interest is to examine whether the mem-
brane-associated MAM can be used as a molecular target
for drug delivery. So we designed a series of cellular exper-
iments in vitro. A MAM-targeted drug carrier was synthe-
sized by conjugating anti-MAM antibody to the surface
protein apo-B100 in human LDL particles, of which dox-
orubicin (Dox) was loaded in the core. As shown by trans-
mission electron microscopy (see Additional file 2), the
morphology and size of the LDL particles containing anti-
MAM antibody and Dox (anti-MAM-LDL-Dox) remain
largely unchanged.
The specific binding and cytotoxic effect of the anti-MAM-
LDL-Dox were tested by using HAEC and MB415 cells.
The specific binding of the LDL-Dox to the LDL receptor
positive HAEC cells were shown in Figure 5B and the cyto-
toxic effect of the particles was shown in Figure 5H. The
surface modification of LDL with anti-MAM antibody
altered the binding capacity of the resultant LDL particles.
The anti-MAM-LDL-Dox particles do not bind to the
HAEC cells to kill the cells as shown in Figure 5C and Fig-
ure 5I respectively. However, the anti-MAM-LDL-Dox par-
ticles specifically bound to the MAM positive MB415
breast cancer cells and killed most of the cells in the field
(Figure 5L). On the other hand, with the anti-MAM mod-
ification on the surface apoB-100 protein, the Dox loaded
LDL particles had no/little binding and cytotoxic effects
on HAEC cells (Figure 5I), indicating that the antibody
medication redirect the binding of LDL particles. Our data
strongly suggested that MAM protein on the surface of
breast cancer cells may serve as a molecular marker for
drug delivery.
Discussion
Several evidences have shown the secretory nature of
MAM protein. For examples, MAM is secreted in the
medium of cultured MAM positive breast cancer cells
[16]; it is detectable in the serum of breast cancer patients
[17]; and the MAM positive stains are largely confined to
the cytoplasm of breast cancer cells by the immunohisto-
chemical study [18]. With the predictive analysis on the
structure of MAM protein, we proposed that some of
MAM proteins stay association with the membrane of
breast cancer cells after secretion. In this report, we pro-
vided three lines of evidences to support our hypothesis.
Immunohistochemical stain of MAM in breast cancer and  non-cancerous tissues Figure 3
Immunohistochemical stain of MAM in breast cancer 
and non-cancerous tissues. Three types of MAM stain 
patterns were observed – cytoplasmic (A and C), membra-
nous (B), and luminary surface stain (D). The number of pos-
itive cells and intensity of the MAM immunostain in cancer 
tissues are much higher and stronger than those in the adja-
cent benign breast tissues. (Images taken by 40× objective 
lens).
Panel One: Incubation of MB361 cells with anti-MAM anti- body and induction of cell apoptosis Figure 4
Panel One: Incubation of MB361 cells with anti-MAM 
antibody and induction of cell apoptosis. Cell viability 
assay was conducted after incubation of MB361 breast can-
cer cells with anti-MAM. The number of the dead cells (in 
red color) was found higher in the anti-MAM incubated can-
cer cells (B), as compared with that in the non-incubated 
MB361 cells (A). There were no or few dead HAEC cells 
(C). The images were taken with objective lens 10×. Panel 
Two: Western blot assay for the pro-PARP-1 (100 kDa) and 
activated PARP-1 (89 kDa) in the protein lysates of MDA-
MB361, T47D, and HAEC cells. The Con – control cells with 
no anti-MAM antibody inoculation, MAM – cells with anti-
MAM antibody inoculation.Cancer Cell International 2009, 9:8 http://www.cancerci.com/content/9/1/8
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MAM protein was detected in the membrane fraction of
the breast cancer cells at first by Western blot assay; Sec-
ondly, the binding of the FITC-labeled anti-MAM anti-
body was found on the breast cancer cells as visualized by
fluorescent microscope; and the third, two MAM immu-
nohistochemical stain patterns were identified in breast
tissues (the membrane and luminary stain patterns) that
are linked with the membrane-associated MAM proteins.
In fact, immunohistochemical stain of MAM protein was
studied in human breast cancers previously [18]. The
membrane and luminary stain patterns somehow were
not described or might be overlooked. Based upon the
predictive analysis, we proposed that the N-end of the
protein may serve as a potential transmembrane domain.
This fragment is, however, partially overlapped with the
"signal peptide" predicted by Watson and Fleming [1].
There are two possible pathways for the mammaglobin
after being synthesized. The first one may happens after
the "signal peptide" is cleaved, then mammaglobin is
becoming a cytoplasmic protein and secreted. If the "sig-
nal peptide" is not cleaved by some reasons, the second
pathway may happen that the protein may be transported
and attached to the membrane through this transmem-
brane domain to become a membrane-associated protein.
Our results clearly showed that both cytoplasmic and
membrane mammaglobin existed in breast cancer cells,
indicating both pathways are functional. The detail
molecular mechanisms remain to be demonstrated.
MAM has been investigated as a molecular marker for
developing breast cancer therapeutic tools. Viehl et al
developed a MAM and Tat fusion protein, which could
transduce dendritic cells to stimulate the production of
the MAM-specific CD4+ and CD8+ T cells. The simultane-
ous activation of these T cells may lead to an improved
overall immune response to the MAM-positive breast can-
cer [19]. Goedegebuure et al proposed a novel strategy to
kill the targeted breast cancer cells by conjugating anti-
MAM antibody to the beta-lactamase gene (βL) [20]. The
βL induces cancer killing by converting the prodrug, 7-(4-
carboxybutanamido) cephlasporin mustard to a cytotoxic
compound [21]. Demonstration of the membrane-associ-
ated MAM protein on breast cancer cells strongly supports
these therapeutic strategies, particularly when anti-MAM
antibody is used as the targeting motif for drug delivery.
Herceptin is a FDA approved targeted therapeutic anti-
body. It binds to Her-2/neu receptor on the membrane of
breast cancer cells and causes a rapid cascade of reactions
resulting in cell apoptosis [22]. While Herceptin proves to
be a therapeutic agent in its own, it also has the ability to
serve as a drug carrier for even more effective and less
intrusive cancer therapy. However, Her-2 is only expressed
in about 20% of breast cancers, which means that the
remaining 80% of the cancer patients with Her-2 negative
expression cannot take the advantage of this treatment
[23]. Mammaglobin may be a complementary biomarker
for the targeted breast cancer therapy because of its high
and exclusive expression in breast cancer tissues [17].
LDL, with its nanoscale dimension and capacity of pene-
trating solid tumor [24], has become an attractive
nanovector for delivery of a wide range of hydrophobic
compounds. As an endogenous carrier for transporting
Specificity and cytotoxicity assay of the synthesized MAM  targeted LDL particles Figure 5
Specificity and cytotoxicity assay of the synthesized 
MAM targeted LDL particles. The images (A-C) show 
the cell binding and endocytosis of free Dox, LDL-Dox, and 
anti-MAM-LDL-Dox. Obvious Dox uptake was found in 
HAEC cells when the cells were incubated with free Dox and 
LDL-Dox (Dox is red fluorogenic), but not in the cells incu-
bated with the anti-MAM-LDL-Dox indicating that conjuga-
tion of anti-MAM blocks the binding sites of LDL to LDLR. 
The LDL-Dox and free Dox incubations are served as posi-
tive controls in this experiment. The images (D-F) are 
matched phase images (A-C). The images (G-I) show the 
results of the cell viability assays after incubation with free 
Dox, LDL-Dox, and anti-MAM-LDL-Dox, many dead cells 
(red color) were found when the HAEC cells were incubated 
with free Dox and LDL-Dox, but few dead cells were shown 
when they were incubated with anti-MAM-LDL-Dox (most 
of the cells are green). The images (J-L) show the cytotoxici-
ties of free Dox, LDL-Dox and Anti-MAM-LDL-Dox to 
MB415 Cells. As shown, most of the cells were dead (small 
and red) when they were treated by free Dox and anti-
MAM-LDL-Dox; while only a few dead cells were found dead 
when they were treated by LDL-Dox. The images were 
taken with objective lens 10×.Cancer Cell International 2009, 9:8 http://www.cancerci.com/content/9/1/8
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cholesterol and other lipids, LDL circulates in blood,
across vascular endothelial linings and into the cells of tis-
sues via LDL receptor-mediated pathways [25]. Because of
the high cholesterol demand for synthesizing new cell
membrane, some types of cancer cells over express LDL
receptor (LDLR) [26]. Therefore, LDL particles have been
used as nanovectors for the selective delivery of diagnostic
and therapeutic agents to tumor cells that over express
LDLR [25,27]. To use LDL as a drug delivery system for
treatment of cancers that do not express LDLR, however,
LDL has to be modified and redirected to alternative
tumor molecular targets. The receptor-binding moieties of
apoB-100 protein in LDL have highly basic domains con-
taining Lys residues. If these Lys residues are modified, the
binding capacity of this protein to the LDLR is essentially
abolished [28,29]. Meanwhile, these basic residues can be
used for conjugating other motifs and redirect the modi-
fied LDL to alternative tumor specific targets. Zheng et al
conjugated folic acid (FA) to the apoB-100 protein of LDL
and rerouted the modified LDL from their normal recep-
tors (LDLR) to cancer-associated FA receptor (FR) [28].
The major advantages of LDL as nanovector include that
it is completely biodegradable, having no immunogenic-
ity, and containing components to which drugs or diag-
nostic agents can be attached by physical or chemical
manipulation [30]. The drawbacks of LDL, however, may
include its limited availability and low drug loading
capacity [31]. The cost for in vivo animal experiment using
LDL such a drug deliver system will be extremely high. In
this study, LDL was used as a prototypical vector to test
our concept of the MAM-oriented drug delivery.
In our experiments, some MB-361 cells were found
detached from the culture dishes with anti-MAM antibody
incubation. It was initially considered as the loss of cell
adhesion due to cell apoptotic death. To prove this
assumption, we incubated the MB361 cells with anti-
MAM antibody. By western blot assays we failed to detect
any expression level changes of some apoptotic related
proteins such as caspase-3 and Bax-1, although a weak
band of the activated PARP-1 protein, a marker of cell
apoptosis, was detected in the MB361 cell lysate. In addi-
tion, the cell viability assays of the cultured cancer cells
revealed only limited cell death. These data indicated that
the loss of cell adhesion caused by anti-MAM incubation
may not due to cell apoptosis.
In summary, we first identified a small fragment at the N-
end of MAM as a potential transmembrane domain in a
computer based analysis, and then demonstrated the pres-
ence of the membrane-associated MAM in both benign
and malignant breast epithelium. Although the specific
binding of anti-MAM antibody to the membrane-bound
MAM in vitro didn't trigger apparent cell apoptosis, the
synthesized MAM targeting LDL particles seemed to be a
functional drug carrier tested in vitro. MAM may become
an attractive biomarker for development of breast cancer
targeted therapies.
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